The Lancet
Orforglipron, an oral small-molecule GLP-1 receptor agonist, for the treatment of obesity in people with type 2 diabetes (ATTAIN-2): a phase 3, double-blind, randomised, multicentre, placebo-controlled trial
経口低分子GLP-1受容体作動薬オルフォグリプロンによる2型糖尿病患者の肥満治療(ATTAIN-2):第Ⅲ相、二重盲検、ランダム化、多施設、プラセボ対照試験